Results 101 to 110 of about 792 (133)
Treatment of functionally nonsignificant vulnerable plaques in multivessel STEMI: design of the VULNERABLE trial. [PDF]
REC Interv CardiolGómez-Lara J, López-Palop R, Rúmiz E, Jurado-Román A, Gómez-Menchero A, Valencia J, Fernández E, Gonçalves Ramírez LR, Brugaletta S, Millán R, Cortés C, Tejedor P, Gutiérrez-Barrios A, Flores X, Cid-Álvarez AB, García-Blas S, García-Camarero T, Linares Vicente JA, Vaquerizo B, Córdoba Soriano JG, Caballero J, Cardenal Piris RM, Sánchez-Elvira G, Oyarzabal L, Pernigotti A, Tramullas A, Antuña P, Rodríguez-Leor O, Ojeda S, Rossello X, Gómez-Hospital JA, Bermejo J, García-García HM, Pérez de Prado A, Gutiérrez-Ibañes E. +34 moreeuropepmc +1 more sourceViral Suppression, Viral Failure, and Safety Outcomes in Children and Adolescents With HIV on Dolutegravir in Europe and Thailand. [PDF]
Clin Infect DisScott K, O'Rourke J, Jackson C, Ene L, Galli L, Goetghebuer T, Henegar C, Königs C, Marczyńska M, Naver L, Noguera-Julian A, Paioni P, Ramos JT, Smith B, Songtaweesin WN, Spoulou V, Tantawarak N, Turkova A, Vannappagari V, Volokha A, Bamford A, Castro H, Chappell E, Dalla Valle G, Foster C, Guillén Martín S, Prieto Tato LM, Puthanakit T, Sherstiuk H, Shkurka I, Soeria-Atmadja S, Judd A, Crichton S, Collins IJ, European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) study group. +34 moreeuropepmc +1 more sourceDOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain. [PDF]
VirusesSequera-Arquelladas S, Hidalgo-Tenorio C, López-Cortés L, Gutiérrez A, Santos J, Téllez F, Omar M, Ferra-Murcia S, Fernández E, Javier R, García-Vallecillos C, Pasquau J. +11 moreeuropepmc +1 more sourceClustering COVID-19 ARDS patients through the first days of ICU admission. An analysis of the CIBERESUCICOVID Cohort. [PDF]
Crit CareCeccato A, Forne C, Bos LD, Camprubí-Rimblas M, Areny-Balagueró A, Campaña-Duel E, Quero S, Diaz E, Roca O, De Gonzalo-Calvo D, Fernández-Barat L, Motos A, Ferrer R, Riera J, Lorente JA, Peñuelas O, Menendez R, Amaya-Villar R, Añón JM, Balan-Mariño A, Barberà C, Barberán J, Blandino-Ortiz A, Boado MV, Bustamante-Munguira E, Caballero J, Carbajales C, Carbonell N, Catalán-González M, Franco N, Galbán C, Gumucio-Sanguino VD, de la Torre MDC, Estella Á, Gallego E, García-Garmendia JL, Garnacho-Montero J, Gómez JM, Huerta A, Jorge-García RN, Loza-Vázquez A, Marin-Corral J, Martínez de la Gándara A, Martin-Delgado MC, Martínez-Varela I, Messa JL, Muñiz-Albaiceta G, Nieto MT, Novo MA, Peñasco Y, Pozo-Laderas JC, Pérez-García F, Ricart P, Roche-Campo F, Rodríguez A, Sagredo V, Sánchez-Miralles A, Sancho-Chinesta S, Socias L, Solé-Violan J, Suarez-Sipmann F, Tamayo-Lomas L, Trenado J, Úbeda A, Valdivia LJ, Vidal P, Bermejo J, Gonzalez J, Barbe F, Calfee CS, Artigas A, Torres A, CIBERESUCICOVID Project. +72 moreeuropepmc +1 more source